<DOC>
	<DOCNO>NCT01042028</DOCNO>
	<brief_summary>This open multicenter randomize phase I/II study . The main purpose study investigate dose efficacy combination Irinotecan , Cetuximab Everolimus give biweekly patient local advance metastatic pancreatic cancer AFTER progression 1. line treatment Gemcitabine .</brief_summary>
	<brief_title>A Randomised Trial With Irinotecan , Cetuximab Everolimus ( ICE ) Compared Capecitabine Oxaliplatin ( CapOx ) Patients With Gemcitabin Resistant Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Written inform consent obtain prior study entry ? 2 . Patient histologically/cytologically proven , nonresectable metastatic , adenocarcinoma pancreas ? 3 . Progressive disease adjuvant chemotherapy ( within 6 month ) progressive disease first line chemotherapy ? 4 . Former treatment chemotherapeutic agent contain gemcitabine ? 5 . Is age patient ≥ 18 year ? 6 . Is ECOG performance status 01 ? 7 . Is absolute neutrophil count ( ANC ) ≥ 1.5 x 109/l ? 8 . Is platelet count ≥ 75 x 109/l ? 9 . Is total bilirubin ≤1.5 x UNL ( upper normal limit ) ? 10 . Patient normal liver function ? ( If liver metastasis present , upper limit ALAT/SPGT/alk phosph ) ? 11 . Creatinine clearance ≥ 30 ml/min 12 . Is patient capable follow treatment plan evaluation ? 1 . CTC Grade 3 hyperlipidaemia ( &gt; 10.34 mmol/l ) spite treatment 2 . Active former concurrent history malignant neoplasm , last 2 year ? 3 . Any condition therapy , investigator opinion , expose patient risk affect purpose clinical trial ? 4 . Pregnant breast feeding patient ( fertile patient must use contraceptive ) ? 5 . Infections serious medical condition , obstruct patient 's possibility receiving treatment ? ( instance serious heart , metabolic lung disease ) 6 . Known hypersensitivity toward one part treatment ?</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pancreas cancer</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Gemcitabine resistant pancreascancer</keyword>
</DOC>